G Beadle1, P Baade, L Fritschi. 1. Department of Translational Research Laboratory, Queensland Institute of Medical Research, Brisbane, Australia. geoffBe@qimr.edu.au
Abstract
BACKGROUND: Clinical trials frequently report acute myeloid leukemia (AML) as a complication of adjuvant chemotherapy for breast cancer (BC). PATIENTS AND METHODS: This retrospective population-based study investigated AML risk after a prior BC diagnosis and compared the results with women after a prior diagnosis of hematological malignancies (HM), other cancers combined (OCC), and the age-matched Australian female population. RESULTS: Women with a prior BC diagnosis had 2.56 times the risk of developing AML compared with the Australian female population (P<0.001). AML risk was also elevated after prior HM and OCC diagnoses (4.73, P<0.001, and 1.70, P<0.001, respectively). Although the incidence of AML rose sharply with age in all cohorts, the age-specific relative risk was highest in the 30- to 49-age-group and decreased with increasing age. AML risk increased with the duration of follow-up but there was no change of risk during the 23 years of this study. CONCLUSION: AML risk was elevated after a prior diagnosis of BC but there was no evidence of an increasing risk of AML after a BC diagnosis or, in any of the other cancer cohorts, during this era of expansion of the evidence base for more intensive treatments.
BACKGROUND: Clinical trials frequently report acute myeloid leukemia (AML) as a complication of adjuvant chemotherapy for breast cancer (BC). PATIENTS AND METHODS: This retrospective population-based study investigated AML risk after a prior BC diagnosis and compared the results with women after a prior diagnosis of hematological malignancies (HM), other cancers combined (OCC), and the age-matched Australian female population. RESULTS:Women with a prior BC diagnosis had 2.56 times the risk of developing AML compared with the Australian female population (P<0.001). AML risk was also elevated after prior HM and OCC diagnoses (4.73, P<0.001, and 1.70, P<0.001, respectively). Although the incidence of AML rose sharply with age in all cohorts, the age-specific relative risk was highest in the 30- to 49-age-group and decreased with increasing age. AML risk increased with the duration of follow-up but there was no change of risk during the 23 years of this study. CONCLUSION:AML risk was elevated after a prior diagnosis of BC but there was no evidence of an increasing risk of AML after a BC diagnosis or, in any of the other cancer cohorts, during this era of expansion of the evidence base for more intensive treatments.
Authors: Mike G Martin; John S Welch; Jingqin Luo; Matthew J Ellis; Timothy A Graubert; Matthew J Walter Journal: Breast Cancer Res Treat Date: 2009-03-26 Impact factor: 4.872
Authors: Michael O Palumbo; Petr Kavan; Wilson H Miller; Lawrence Panasci; Sarit Assouline; Nathalie Johnson; Victor Cohen; Francois Patenaude; Michael Pollak; R Thomas Jagoe; Gerald Batist Journal: Front Pharmacol Date: 2013-05-07 Impact factor: 5.810